Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Henriksson, Roger
Alternative names
Publications (10 of 230) Show all publications
Hoang-Xuan, K., Deckert, M., Ferreri, A. J., Furtner, J., Gallego Perez-Larraya, J., Henriksson, R., . . . Bromberg, J. E. (2023). European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro-Oncology, 25(1), 37-53
Open this publication in new window or tab >>European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
Show others...
2023 (English)In: Neuro-Oncology, ISSN 1522-8517, E-ISSN 1523-5866, Vol. 25, no 1, p. 37-53Article in journal (Refereed) Published
Abstract [en]

The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.

Place, publisher, year, edition, pages
Oxford University Press, 2023
Keywords
chemotherapy, immunotherapy, primary CNS lymphoma, radiotherapy, treatment
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-203552 (URN)10.1093/neuonc/noac196 (DOI)000854227600001 ()35953526 (PubMedID)2-s2.0-85145954928 (Scopus ID)
Available from: 2023-01-19 Created: 2023-01-19 Last updated: 2023-03-24Bibliographically approved
Rodriguez-Wallberg, K. A., Ahlgren, J., Smedby, K. E., Gorman, J. R., Hellman, K., Henriksson, R., . . . Lampic, C. (2023). Prevalence and predictors for fertility-related distress among 1010 young adults 1.5 years following cancer diagnosis.: results from the population-based fex-can cohort study. Acta Oncologica, 62(12), 1599-1606
Open this publication in new window or tab >>Prevalence and predictors for fertility-related distress among 1010 young adults 1.5 years following cancer diagnosis.: results from the population-based fex-can cohort study
Show others...
2023 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 62, no 12, p. 1599-1606Article in journal (Refereed) Published
Abstract [en]

Background: Cancer treatment during reproductive ages may negatively impact fertility and there is a need of firm knowledge about the prevalence and predictors of fertility-related distress. The aim was to examine fertility-related distress in a population-based sample of young women and men recently treated for cancer and to identify predictors for this outcome.

Material and methods: This nationwide cohort study included 1010 individuals (694 women and 316 men), mean age 34.5 ± 4.9 and 32.1 ± 5.5, respectively, diagnosed with breast, cervical, ovarian, testicular cancers, brain tumors or lymphoma at ages 18–39 in Sweden. Participants completed a survey 1.5-year post-diagnosis to assess fertility-related distress (RCAC), emotional distress (HADS) and self-efficacy, as well as sociodemographic and clinical factors and fertility preservation. Logistic regression was used to examine associations between explanatory factors and high fertility-related distress (RCAC subscale mean >4).

Results: Many participants (69% of women and 47% of men) had previous children and about half reported a wish for future children. High fertility-related distress was more prevalent among women (54%) than men (27%), and women were more likely than men to report distress concerning all but one RCAC dimension after adjustment for sociodemographic factors. Use of fertility preservation was unevenly distributed (15% of women and 71% of men) and was not associated with decreased fertility-related distress. In multivariable logistic regression models, a wish for future children, being single, not having previous children, symptoms of anxiety and low self-efficacy regarding one’s ability to handle threats of infertility were associated with high fertility-related distress.

Conclusion: This nationwide study found a high prevalence of fertility-related distress in young women and men recently treated for cancer and identified sociodemographic and psychological predictors. Fertility preservation was not found to act as a buffer against fertility-related distress, indicating the continuous need to identify strategies to alleviate fertility distress following cancer.

Place, publisher, year, edition, pages
Informa UK Limited, 2023
Keywords
cancer survivorship, Cohort study, fertility distress, parenthood concerns, young adults
National Category
Cancer and Oncology Nursing
Identifiers
urn:nbn:se:umu:diva-216626 (URN)10.1080/0284186X.2023.2272291 (DOI)37909865 (PubMedID)2-s2.0-85175703517 (Scopus ID)
Funder
Swedish Childhood Cancer Foundation, TJ2014-0050Swedish Cancer Society, 20 0170FForte, Swedish Research Council for Health, Working Life and Welfare, 2014-4689The Cancer Research Funds of Radiumhemmet, 161272The Cancer Research Funds of Radiumhemmet, 221363
Available from: 2023-11-21 Created: 2023-11-21 Last updated: 2024-01-03Bibliographically approved
Kinhult, S., Tavelin, B., Löfgren, D., Rosenlund, L., Sandström, M., Strandeus, M. & Henriksson, R. (2023). Regional variation in usage of TTF (Optune) Regional variation i användningen av TTF vid glioblastombehandling: [Regional variation in usage of TTF (Optune)]. Läkartidningen, 120, Article ID 22158.
Open this publication in new window or tab >>Regional variation in usage of TTF (Optune) Regional variation i användningen av TTF vid glioblastombehandling: [Regional variation in usage of TTF (Optune)]
Show others...
2023 (English)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 120, article id 22158Article in journal (Refereed) Published
Abstract [en]

The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide. Based on a randomised trial, showing five months increased survival, TTF has been introduced in the management of patients with good performance status. Data from the Swedish national quality registry for CNS tumours have been analysed for TTF usage. The results demonstrate that 65 percent of the patients accepted treatment with TTF. More than half of the treated patients interrupted treatment due to low compliance or their own wish. Median treatment time was 164 days, with a range from 0 to 774 days. There was a large variation between different regions in how many patients were offered TTF treatment. A non-significant trend to better survival was seen for the group of TTF-treated patients compared to individually matched controls. In summary, TTF is a new treatment for glioblastoma, with potential to prolong survival also in real world patients. Today, the treatment is not offered equally to all patients, despite national guidelines.

Place, publisher, year, edition, pages
Sveriges läkarförbund, 2023
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-212051 (URN)2-s2.0-85164005813 (Scopus ID)
Note

Publicerad på Lakartidningen.se 2023-07-03

Available from: 2023-07-18 Created: 2023-07-18 Last updated: 2023-07-18Bibliographically approved
Walladbegi, J., Henriksson, R., Tavelin, B., Svanberg, A., Larfors, G., Jädersten, M., . . . Jontell, M. (2022). Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial. Bone Marrow Transplantation, 57(2), 191-197
Open this publication in new window or tab >>Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial
Show others...
2022 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 57, no 2, p. 191-197Article in journal (Refereed) Published
Abstract [en]

Cryoprevention (CP) using ice (IC) is an effective strategy to prevent chemotherapy-induced oral mucositis (OM). However, the use of IC may cause adverse reactions and requires water of safe quality to minimize risk of serious infections. This randomized, blinded, parallel group, phase 3 trial was conducted in five Scandinavian centers. Eligible patients were diagnosed with multiple myeloma or lymphoma, scheduled to receive conditioning with high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation (ASCT). Patients were assigned to cooling with IC or a novel intraoral cooling device (ICD). The primary outcome was the highest OM score during the study period, expressed as peak value on the Oral Mucositis Assessment Scale (OMAS–total). When the entire study population (n = 172) was analyzed for peak OMAS–total, the two cooling methods were equally effective. However, when the lymphoma group was analyzed separately, the ICD significantly reduced the peak OMAS–total score to a greater extent compared to IC (x̄ ± SD; 1.77 ± 1.59 vs. 3.08 ± 1.50; p = 0.047). Combined with existing evidence, the results of the present trial confirm that CP is an effective method to prevent OM.

ClinicalTrials.gov. NCT03203733.

Place, publisher, year, edition, pages
Springer Nature, 2022
National Category
Hematology
Identifiers
urn:nbn:se:umu:diva-189557 (URN)10.1038/s41409-021-01512-6 (DOI)000713942300001 ()34728786 (PubMedID)2-s2.0-85118421846 (Scopus ID)
Funder
Vinnova, 2016-04171
Available from: 2021-11-16 Created: 2021-11-16 Last updated: 2022-07-12Bibliographically approved
Hagiwara, A., Schlossman, J., Shabani, S., Raymond, C., Tatekawa, H., Abrey, L. E., . . . Ellingson, B. M. (2022). Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation. Journal of Neuro-Oncology, 159, 509-518
Open this publication in new window or tab >>Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation
Show others...
2022 (English)In: Journal of Neuro-Oncology, ISSN 0167-594X, E-ISSN 1573-7373, Vol. 159, p. 509-518Article in journal (Refereed) Published
Abstract [en]

Purpose: Pseudoprogression (PsP) remains an elusive and clinically important, yet ill-defined, phenomena that, generally, involves a period of early radiographic progression (enhancement) followed by a period of radiographic stability or regression. In the current study, we utilized data from the control arm of a phase III clinical trial in newly-diagnosed glioblastoma to explore imaging characteristics of “clinically-defined PsP”, or early radiographic progression (PFS < 6 months from chemoradiation) followed by a long post-progression residual overall survival (ROS > 12 months).

Methods: One hundred sixty-nine patients with newly-diagnosed GBM from the control arm of the AVAglio trial (NCT00943826) who presented with early radiographic progressive disease (PD) (< 6 months) were included. Clinical characteristics, topographical patterns, and radiomic features were compared between newly-diagnosed GBM exhibiting early PD and early death (< 12-month ROS, “true PD”) with those exhibiting early PD and a long residual survival (> 12-month ROS, “clinically-defined PsP”).

Results: “Clinically-defined PsP” occurred to 38.5% of patients with early PD, and was more associated with MGMT methylation (P = 0.02), younger age (P = 0.003), better neurological performance (P = 0.01), and lower contrast-enhancing tumor volume (P = 0.002) at baseline. GBM showing “true PD” occurred more frequently in the right internal capsule, thalamus, lentiform nucleus, and temporal lobe than those with “clinical PsP”. Radiomic analysis predicted “clinical PsP” with > 70% accuracy on the validation dataset.

Conclusion: Patients with early PD that eventually exhibit “clinically-defined PsP” have distinct clinical, molecular, and MRI characteristics. This information may be useful for treating clinicians to better understand the potential risks and outcome in patients exhibiting early radiographic changes following chemoradiation.

Place, publisher, year, edition, pages
Springer, 2022
Keywords
Chemoradiation, Clinical trial, Newly diagnosed glioblastoma, Pseudoprogression, Radiomics
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-198305 (URN)10.1007/s11060-022-04088-3 (DOI)000826275800001 ()35842871 (PubMedID)2-s2.0-85134492491 (Scopus ID)
Available from: 2022-07-28 Created: 2022-07-28 Last updated: 2023-05-04Bibliographically approved
Alexandra, W., Wettergren, L., Ahlgren, J., Smedby, K. E., Hellman, K., Henriksson, R., . . . Lampic, C. (2021). Fertility-related information received by young women and men with cancer: a population-based survey. Acta Oncologica, 60(8), 976-983
Open this publication in new window or tab >>Fertility-related information received by young women and men with cancer: a population-based survey
Show others...
2021 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 60, no 8, p. 976-983Article in journal (Refereed) Published
Abstract [en]

Background: Infertility is a well-known sequela of cancer treatment. Despite guidelines recommending early discussions about risk of fertility impairment and fertility preservation options, not all patients of reproductive age receive such information.

Aims: This study aimed to investigate young adult cancer patients' receipt of fertility-related information and use of fertility preservation, and to identify sociodemographic and clinical factors associated with receipt of information.

Materials and methods: A population-based cross-sectional survey study was conducted with 1010 young adults with cancer in Sweden (response rate 67%). The inclusion criteria were: a previous diagnosis of breast cancer, cervical cancer, ovarian cancer, brain tumor, lymphoma or testicular cancer between 2016 and 2017, at an age between 18 and 39 years. Data were analyzed using logistic regression models.

Results: A majority of men (81%) and women (78%) reported having received information about the potential impact of cancer/treatment on their fertility. A higher percentage of men than women reported being informed about fertility preservation (84% men vs. 40% women, p < .001) and using gamete or gonadal cryopreservation (71% men vs. 15% women, p < .001). Patients with brain tumors and patients without a pretreatment desire for children were less likely to report being informed about potential impact on their fertility and about fertility preservation. In addition, being born outside Sweden was negatively associated with reported receipt of information about impact of cancer treatment on fertility. Among women, older age (>35 years), non-heterosexuality and being a parent were additional factors negatively associated with reported receipt of information about fertility preservation.

Conclusion: There is room for improvement in the equal provision of information about fertility issues to young adult cancer patients.

Place, publisher, year, edition, pages
Taylor & Francis, 2021
Keywords
Cancer, fertility, fertility preservation, oncofertility, reproductive oncology, hematology
National Category
Obstetrics, Gynecology and Reproductive Medicine Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:umu:diva-187966 (URN)10.1080/0284186X.2021.1900909 (DOI)000632810900001 ()33764839 (PubMedID)2-s2.0-85103221609 (Scopus ID)
Funder
Swedish Childhood Cancer Foundation, TJ2014-0050Swedish Cancer Society, CAN 2013/886Swedish Cancer Society, CAN 2016/615Swedish Cancer Society, 19 0196PjForte, Swedish Research Council for Health, Working Life and Welfare, 2014-4689The Cancer Research Funds of Radiumhemmet, 161272Vårdal Foundation, 2014-0098Swedish Research Council, 2017-01530
Available from: 2021-09-28 Created: 2021-09-28 Last updated: 2024-07-02Bibliographically approved
Thurin, E., Rydén, I., Skoglund, T., Smits, A., Gulati, S., Hesselager, G., . . . Jakola, A. S. (2021). Impact of meningioma surgery on use of antiepileptic, antidepressant, and sedative drugs: A Swedish nationwide matched cohort study. Cancer Medicine, 10(9), 2967-2977
Open this publication in new window or tab >>Impact of meningioma surgery on use of antiepileptic, antidepressant, and sedative drugs: A Swedish nationwide matched cohort study
Show others...
2021 (English)In: Cancer Medicine, E-ISSN 2045-7634, Vol. 10, no 9, p. 2967-2977Article in journal (Refereed) Published
Abstract [en]

Background: Meningioma is the most common primary intracranial tumor and surgery is the main treatment modality. As death from lack of tumor control is rare, other outcome measures like anxiety, depression and post-operative epilepsy are becoming increasingly relevant. In this nationwide registry-based study we aimed to describe the use of antiepileptic drugs (AED), antidepressants and sedatives before and after surgical treatment of an intracranial meningioma compared to a control population, and to provide predictors for continued use of each drug-group two years after surgery.

Methods: All adult patients with histopathologically verified intracranial meningiomas were identified in the Swedish Brain Tumor Registry and their data were linked to relevant national registries after assigning five matched controls to each patient. We analyzed the prescription patterns of antiepileptic drugs (AED), antidepressants and sedative drugs in the two years before and the two years following surgery.

Results: For the 2070 patients and 10312 controls identified the use of AED, antidepressants and sedatives was comparable two years before surgery. AED use at time of surgery was higher for patients than for controls (22.2% vs. 1.9%, p < 0.01), as was antidepressant use (12.9% vs. 9.4%, p < 0.01). Both AED and antidepressant use remained elevated after surgery, with patients having a higher AED use (19.7% vs. 2.3%, p < 0.01) and antidepressant use (14.8% vs. 10.6%, p < 0.01) at 2 years post-surgery. Use of sedatives peaked for patients at the time of surgery (14.4% vs. 6.1%, p < 0.01) and remained elevated at two years after surgery with 9.9% versus 6.6% (p < 0.01). For all the studied drugs, previous drug use was the strongest predictor for use 2 years after surgery.

Conclusion: This nationwide study shows that increased use of AED, antidepressants and sedatives in patients with meningioma started perioperatively, and remained elevated two years following surgery.

Place, publisher, year, edition, pages
John Wiley & Sons, 2021
Keywords
anti-epileptic drugs, antidepressant, neurosurgery, primary brain tumor, quality of life
National Category
Neurology
Identifiers
urn:nbn:se:umu:diva-182158 (URN)10.1002/cam4.3868 (DOI)000633503300001 ()33773085 (PubMedID)2-s2.0-85103215435 (Scopus ID)
Funder
Swedish Research Council, 2017‐00944
Available from: 2021-04-22 Created: 2021-04-22 Last updated: 2024-01-17Bibliographically approved
Herdenberg, C., Mutie, P., Billing, O., Abdullah, A., Strawbridge, R. J., Dahlman, I., . . . Hedman, H. (2021). LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes. Communications Biology, 4(1), Article ID 90.
Open this publication in new window or tab >>LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes
Show others...
2021 (English)In: Communications Biology, E-ISSN 2399-3642, Vol. 4, no 1, article id 90Article in journal (Refereed) Published
Abstract [en]

Leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins have been implicated as regulators of growth factor signaling; however, the possible redundancy among mammalian LRIG1, LRIG2, and LRIG3 has hindered detailed elucidation of their physiological functions. Here, we show that Lrig-null mouse embryonic fibroblasts (MEFs) are deficient in adipogenesis and bone morphogenetic protein (BMP) signaling. In contrast, transforming growth factor-beta (TGF-beta) and receptor tyrosine kinase (RTK) signaling appeared unaltered in Lrig-null cells. The BMP signaling defect was rescued by ectopic expression of LRIG1 or LRIG3 but not by expression of LRIG2. Caenorhabditis elegans with mutant LRIG/sma-10 variants also exhibited a lipid storage defect. Human LRIG1 variants were strongly associated with increased body mass index (BMI) yet protected against type 2 diabetes; these effects were likely mediated by altered adipocyte morphology. These results demonstrate that LRIG proteins function as evolutionarily conserved regulators of lipid metabolism and BMP signaling and have implications for human disease. Herdenberg et al. show that adipogenesis and BMP signaling are altered in mouse cells deficient in LRIG (Leucine-rich repeats and immunoglobulin-like domains) proteins. They find that mutant LRIG/sma-10 variant worms exhibit lipid storage defects and that human LRIG1 variants are associated with higher body mass index, yet protect against type 2 diabetes. This study suggests an evolutionarily conserved role of LRIG proteins for lipid metabolism and BMP signaling.

Place, publisher, year, edition, pages
Springer Nature, 2021
National Category
Cell and Molecular Biology
Identifiers
urn:nbn:se:umu:diva-180823 (URN)10.1038/s42003-020-01613-w (DOI)000613509200014 ()33469151 (PubMedID)2-s2.0-85099541477 (Scopus ID)
Available from: 2021-02-26 Created: 2021-02-26 Last updated: 2024-07-02Bibliographically approved
Rydén, I., Thurin, E., Carstam, L., Smits, A., Gulati, S., Henriksson, R., . . . Store Jakola, A. (2021). Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study. BMC Cancer, 21(1), Article ID 248.
Open this publication in new window or tab >>Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study
Show others...
2021 (English)In: BMC Cancer, E-ISSN 1471-2407, Vol. 21, no 1, article id 248Article in journal (Refereed) Published
Abstract [en]

Background: Low-grade glioma (LGG) is a relatively rare type of brain tumour. The use of antidepressant, sedative and anti-epileptic drugs can reflect the burden of the disease. While epilepsy is well-described in patients with LGG, less is known about depression and anxiety.

Methods: We used nationwide registers to study the use (dispense) of antidepressants, sedatives, and anti-epileptic drugs (AEDs) before and after histopathological LGG diagnosis (WHO grade II). A total of 485 adult patients with a first-time diagnosis and a matched control cohort (n = 2412) were included. Patterns of use were analysed from one year prior to until one year following index date (date of surgery). Logistic regression analysis identified predictors for postoperative use.

Results: At one year before index date, patients were dispensed AEDs 4 times more than controls, while antidepressants and sedatives were similar. Sedatives and AED peaked shortly after index date at 25 and 69%, respectively. AEDs then stabilized while sedatives decreased rapidly. For antidepressants, a delayed increase was seen after index date, stabilizing at 12%. At one year after index date, the use of antidepressants, sedatives, and AEDs among patients was 2, 3, and 26 times higher, respectively, compared to controls. Predictor for use of AEDs and sedatives at one year following index was previous use and/or a related diagnosis. Female sex and later index year were additional predictors for antidepressants.

Conclusions: Use of antidepressants, sedatives and AEDs is elevated following diagnosis of LGG. Antidepressants were more commonly dispensed to female patients and in recent years.

Place, publisher, year, edition, pages
BioMed Central, 2021
Keywords
Anti-anxiety agents, Anticonvulsants, Antidepressive agents, Glioma; low-grade glioma
National Category
Neurosciences Neurology
Identifiers
urn:nbn:se:umu:diva-181785 (URN)10.1186/s12885-021-07939-w (DOI)000627387800006 ()2-s2.0-85102702794 (Scopus ID)
Funder
Swedish Research Council, 2017–00944
Note

Errata: Rydén, I., Thurin, E., Carstam, L. et al. Correction: Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study. BMC Cancer 22, 350 (2022). DOI: 10.1186/s12885-022-09400-y

Available from: 2021-04-01 Created: 2021-04-01 Last updated: 2024-07-04Bibliographically approved
Gatson, N. T., Barnholtz-Sloan, J., Drappatz, J., Henriksson, R., Hottinger, A. F., Hinoul, P., . . . Glas, M. (2021). Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Frontiers in Oncology, 11, Article ID 679702.
Open this publication in new window or tab >>Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic
Show others...
2021 (English)In: Frontiers in Oncology, E-ISSN 2234-943X, Vol. 11, article id 679702Article in journal (Refereed) Published
Abstract [en]

Background: The COVID-19 pandemic has placed excessive strain on health care systems and is especially evident in treatment decision-making for cancer patients. Glioblastoma (GBM) patients are among the most vulnerable due to increased incidence in the elderly and the short survival time. A virtual meeting was convened on May 9, 2020 with a panel of neuro-oncology experts with experience using Tumor Treating Fields (TTFields). The objective was to assess the risk-to-benefit ratio and provide guidance for using TTFields in GBM during the COVID-19 pandemic.

Panel Discussion: Topics discussed included support and delivery of TTFields during the COVID-19 pandemic, concomitant use of TTFields with chemotherapy, and any potential impact of TTFields on the immune system in an intrinsically immunosuppressed GBM population. Special consideration was given to TTFields' use in elderly patients and in combination with radiotherapy regimens. Finally, the panel discussed the need to better capture data on COVID-19–positive brain tumor patients to analyze longitudinal outcomes and changes in treatment decision-making during the pandemic.

Expert Opinion: TTFields is a portable home-use device which can be managed via telemedicine and safely used in GBM patients during the COVID-19 pandemic. TTFields has no known immunosuppressive effects which is important during a crisis where other treatment methods might be limited, especially for elderly patients with multiple co-morbidities. It is too early to estimate the full impact of COVID-19 on the global healthcare system and on patient outcomes and the panel strongly recommended collaboration with existing cancer COVID-19 registries to follow CNS tumor patients.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2021
Keywords
COVID-19, elderly, glioblastoma, recurrent glioblastoma, tumor treating fields
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-184448 (URN)10.3389/fonc.2021.679702 (DOI)000652638300001 ()34026655 (PubMedID)2-s2.0-85107231995 (Scopus ID)
Available from: 2021-06-14 Created: 2021-06-14 Last updated: 2024-01-17Bibliographically approved
Organisations

Search in DiVA

Show all publications